All News

When starting chemotherapy, I was expecting hair and weight loss, but was caught off guard when my mouth began to hurt.

CAR-T cell therapies have not always been easy to access for patients with myeloma, though that is slowly changing, an expert explained.

Watch Dr. Laura C. Michaelis, from the Medical College of Wisconsin, discuss the current and future management of essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Patients with inactive early-stage chronic lymphocytic leukemia may benefit from a wait-and-watch approach compared with immediate treatment with Imbruvica, findings from a phase 3 trial showed.

A survey of cancer centers found that the majority of large centers are facing cisplatin and carboplatin shortages, and some are changing or delaying treatment because of it.

Sure, knowledge is power, but there’s comfort in naïveté, too, when it comes to expectations for cancer care.

Jakafi led to improved symptom score and spleen volume reductions in patients with myelofibrosis, regardless of anemia or transfusion status, recent research showed.

Watch Dr. Lucia Masarova, from MD Anderson Cancer Center, discuss risk stratifying patients with essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Because MPNs can cause chronic disease that spans years or even decades, some patients need their significant other to become their caregiver.

Iclusig plus reduced-intensity chemotherapy led to improved outcomes for patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia, and should be the new standard of care, one expert said.

An ongoing trial is examining Calquence in older or frail patients with chronic lymphocytic leukemia — a group that is typically left out of clinical trials.

Patients and their caregivers may benefit from community support and education following an MPN diagnosis

Cancer taught me not to worry about the little things.

From Shannen Doherty’s announcement that her breast cancer spread to her brain to a nonprofit being established in memory of the late YouTuber, Technoblade, here’s what’s happening in the oncology space this week.

I transformed my mindset to maximize healing before, during and after prostate cancer treatment.

Drink this between meals to help gain or maintain a healthy weight during and after cancer treatment.

Treatments with JAK inhibitors are continuing to make their way into the MPN space, providing symptom relief, but not yet a cure.

Artificial intelligence is becoming increasingly popular and can even write generic poems about the cancer experience. However, I feel that they cannot compare to the writings of people who actually lived with the disease.

For patients with a history of cancer or who are genetically predisposed to it — as well as the general population — unintended weight loss may be the first sign of the disease, research showed.

After seeing my friend get off the merry-go-round of advanced cancer treatment, I am starting to think more seriously and soberly about my next options and decisions.

Patients with MPNs should consult with their treating physician to individualize a healthy, nutritious diet to help ease symptoms.

Researchers may have uncovered new ways to help patients with accelerated-phase and blast-phase MPNs live longer by borrowing therapies from other blood cancers.

I recently underwent genetic testing to see if I had any mutations that could be associated with an increased cancer risk.

Patients with non-small cell lung cancer who cleared 50% or more of cancerous DNA from their blood by their fourth treatment cycle tended to have better outcomes on maintenance therapy, research showed.

Meaningful improvements in survival were obtained with Zejula maintenance therapy compared with placebo in patients with advanced ovarian cancer that was newly diagnosed.

Tumor treating fields therapy “is a potentially paradigm-shifting new treatment modality” for metastatic non-small cell lung cancer, says Dr. Ticiana Leal.

Patients with advanced-stage classic Hodgkin lymphoma had a longer progression-free survival rate with Opdivo plus AVD, a chemotherapy regimen, compared with Adcetris plus AVD.